Axsome Therapeutics Crecimiento futuro

Future controles de criterios 6/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Axsome Therapeutics de 60% y 35.5% por año respectivamente. Se prevé que el BPA crezca en un 59.9% al año. Se espera que la rentabilidad financiera sea de 80.7% en 3 años.

Información clave

65.1%

Tasa de crecimiento de los beneficios

65.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.8%
Tasa de crecimiento de los ingresos	37.2%
Rentabilidad financiera futura	63.6%
Cobertura de analistas	Good
Última actualización	27 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09

Recent updates

Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments

May 10

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce

Dec 27

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Dec 12

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Sep 12

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Aug 08

Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts

May 13

Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 03

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?

Mar 01

Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?

Nov 14

Axsome Therapeutics: Clear Path Ahead For AXS07

Oct 05

Axsome to resubmit marketing application for migraine therapy in Q3 2023

Sep 29

Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity

Sep 16

Axsome begins enrolling in late-stage study of migraine drug AXS-07

Sep 01

Axsome gains 19% as FDA approves depression therapy

Aug 19

Axsome Therapeutics Q2 2022 Earnings Preview

Aug 08

Axsome: Breaking Bearish Trend

Jul 26

Axsome: One Step At A Time

Jul 01

Axsome And AXS-05: A Special Situation

May 02

Axsome: A Growth Transition

Apr 13

Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst

Apr 03

Axsome: A Biotech With Potential Approval Of Several Drugs In Coming Years

Mar 19

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:AXSM - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	1,117	291	191	223	12
12/31/2025	671	-23	-45	-16	16
12/31/2024	376	-233	-191	-131	16
3/31/2024	251	-296	-193	-193	N/A
12/31/2023	271	-239	-146	-145	N/A
9/30/2023	223	-202	-143	-142	N/A
6/30/2023	182	-184	-112	-111	N/A
3/31/2023	145	-159	-90	-90	N/A
12/31/2022	50	-187	-117	-117	N/A
9/30/2022	26	-160	-118	-118	N/A
6/30/2022	9	-150	-123	-122	N/A
3/31/2022	N/A	-141	-114	-114	N/A
12/31/2021	N/A	-130	-109	-108	N/A
9/30/2021	N/A	-126	-100	-100	N/A
6/30/2021	N/A	-114	-89	-89	N/A
3/31/2021	N/A	-100	-82	-82	N/A
12/31/2020	N/A	-103	-79	-78	N/A
9/30/2020	N/A	-99	-75	-75	N/A
6/30/2020	N/A	-95	-70	-70	N/A
3/31/2020	N/A	-90	-60	-60	N/A
12/31/2019	N/A	-68	-46	-46	N/A
9/30/2019	N/A	-53	-39	-39	N/A
6/30/2019	N/A	-42	-34	-34	N/A
3/31/2019	N/A	-37	-33	-33	N/A
12/31/2018	N/A	-31	-30	-30	N/A
9/30/2018	N/A	-29	-27	-27	N/A
6/30/2018	N/A	-27	-27	-27	N/A
3/31/2018	N/A	-26	-27	-27	N/A
12/31/2017	N/A	-29	N/A	-26	N/A
9/30/2017	N/A	-29	N/A	-27	N/A
6/30/2017	N/A	-30	N/A	-26	N/A
3/31/2017	N/A	-29	N/A	-24	N/A
12/31/2016	N/A	-27	N/A	-21	N/A
9/30/2016	N/A	-23	N/A	-16	N/A
6/30/2016	N/A	-21	N/A	-13	N/A
3/31/2016	N/A	-16	N/A	-10	N/A
12/31/2015	N/A	-12	N/A	-7	N/A
9/30/2015	N/A	-10	N/A	-7	N/A
6/30/2015	N/A	-6	N/A	-6	N/A
3/31/2015	N/A	-6	N/A	-5	N/A
12/31/2014	N/A	-6	N/A	-5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que AXSM sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que AXSM sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que AXSM sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (35.5% al año) de AXSM crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (35.5% al año) de AXSM crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de AXSM sea muy elevada dentro de 3 años (80.7%).

Axsome Therapeutics Crecimiento futuro

Future controles de criterios 6/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 25%

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Forecast breakeven date pushed back to 2026

Consensus EPS estimates fall by 21%

Consensus EPS estimates fall by 12%, revenue upgraded

Consensus revenue estimates increase by 45%

Recent updates

Consensus EPS estimates fall by 25%

Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Forecast breakeven date pushed back to 2026

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Axsome Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Axsome Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024

COO & Secretary exercised options and sold US$1.9m worth of stock

Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Independent Lead Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges

Full year 2023 earnings: EPS misses analyst expectations

Axsome Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Axsome Therapeutics, Inc. Presents Results of the Accord Trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease Agitation at its Clinical Trials on Alzheimer's Disease 2023 Conference

Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors

Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors

Axsome Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Independent Director notifies of intention to sell stock

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Consensus EPS estimates fall by 12%, revenue upgraded

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Axsome Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Axsome Therapeutics Initiates Focus Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (Adhd) in Adults

Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Axsome Therapeutics, Inc. to Present New Sunosi Data at Sleep 2023

Consensus revenue estimates increase by 45%

Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts

Consensus EPS estimates fall by 27%

Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?

Axsome Therapeutics, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Forecast to breakeven in 2025

Axsome Therapeutics Presents New Data from the Evolve Open-Label Trial Demonstrating Effects of Auvelity® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder At the American College of Neuropsychopharmacology (Acnp) 2022 Annual Meeting

Price target increased to US$109

Axsome Therapeutics, Inc. Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

Insufficient new directors

Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?

Axsome Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Axsome Therapeutics, Inc. Announces Availability of Auvelity, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

No longer forecast to breakeven

Axsome Therapeutics: Clear Path Ahead For AXS07

Axsome Therapeutics, Inc. Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the Sharp Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea

Axsome Therapeutics, Inc. Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting

Axsome to resubmit marketing application for migraine therapy in Q3 2023

Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity

Axsome Therapeutics, Inc. Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

Forecast to breakeven in 2024

Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research

Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor

Axsome begins enrolling in late-stage study of migraine drug AXS-07

Price target increased to US$92.93

Axsome Therapeutics Announces FDA Approval of AUVELITY(TM), the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

Axsome gains 19% as FDA approves depression therapy

No longer forecast to breakeven

Axsome Therapeutics Q2 2022 Earnings Preview

Axsome Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Axsome: Breaking Bearish Trend

Consensus forecasts updated

Axsome: One Step At A Time